Abstract
Substantial progress is being made in endocrine therapy for breast cancer. Here we review the results from recent trials, highlight key areas of current translational research, and discuss the potential for brief preoperative studies to identify molecular markers predicting outcome in the individual patient. A key challenge for translational research is to optimize endocrine therapy based on patient and tumor characteristics. A further challenge is to identify tumors with acquired or innate resistance and to develop the use of signal transduction inhibitors in combination with endocrine therapy as a means to overcome resistance. Key to the success of such approaches will be clinical trial designs that incorporate appropriate tumor selection and validation of biomarkers predicting benefit.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
